These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24398781)

  • 1. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
    Sensi M; Preda F; Trevisani L; Contini E; Gragnaniello D; Capone JG; Sette E; Golfre-Andreasi N; Tugnoli V; Tola MR; Quatrale R
    J Neural Transm (Vienna); 2014 Jun; 121(6):633-42. PubMed ID: 24398781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Catalan MJ; Molina-Arjona JA; Mir P; Cubo E; Arbelo JM; Martinez-Martin P;
    J Neurol; 2018 Jun; 265(6):1279-1287. PubMed ID: 29557989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease.
    Zibetti M; Angrisano S; Dematteis F; Artusi CA; Romagnolo A; Merola A; Lopiano L
    J Neurol Sci; 2018 Feb; 385():105-108. PubMed ID: 29406886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait.
    Cossu G; Ricchi V; Pilleri M; Mancini F; Murgia D; Ricchieri G; Mereu A; Melis M; Antonini A
    Neurol Sci; 2015 Sep; 36(9):1683-6. PubMed ID: 25939726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
    Zibetti M; Merola A; Ricchi V; Marchisio A; Artusi CA; Rizzi L; Montanaro E; Reggio D; De Angelis C; Rizzone M; Lopiano L
    J Neurol; 2013 Jan; 260(1):105-14. PubMed ID: 22772358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Duodopa
    Ciurleo R; Corallo F; Bonanno L; Lo Buono V; Di Lorenzo G; Versaci R; Allone C; Palmeri R; Bramanti P; Marino S
    J Neurol; 2018 Sep; 265(9):2005-2014. PubMed ID: 29951701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
    Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
    Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
    Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
    Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
    Cáceres-Redondo MT; Carrillo F; Lama MJ; Huertas-Fernández I; Vargas-González L; Carballo M; Mir P
    J Neurol; 2014 Mar; 261(3):561-9. PubMed ID: 24477490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
    Tessitore A; Marano P; Modugno N; Pontieri FE; Tambasco N; Canesi M; Latorre A; Lopiano L; Sensi M; Quatrale R; Solla P; Defazio G; Melzi G; Costanzo AM; Gualberti G; di Luzio Paparatti U; Antonini A
    J Neurol; 2018 May; 265(5):1124-1137. PubMed ID: 29516169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
    Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study].
    Skoromets AA; Odinak MM; Yakupov EZ; Litvinenko IV; Zalyalova ZA; Timofeeva AA; Kirtaev SY; Bogdanov RR; Agafina AS; Chatamra K; Robieson W; Benesh J; Latypova GR; Ershova MV; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):22-31. PubMed ID: 28374689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden.
    Santos-García D; Añón MJ; Fuster-Sanjurjo L; de la Fuente-Fernández R
    Eur J Neurol; 2012 Sep; 19(9):1261-5. PubMed ID: 22248261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.